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S U M M A R Y
Objectives: Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae are on the increase. Although cefmetazole is stable in vitro against the
hydrolyzing activity of ESBLs, no clinical study has ever evaluated its role in infections caused by these
organisms. We therefore evaluated the efﬁcacy of cefmetazole compared to carbapenems against
pyelonephritis caused by ESBL-producing Enterobacteriaceae.
Methods: A retrospective chart review was conducted at a tertiary care hospital from August 2008 to July
2010. Chart reviews were done for patients with ESBL-producing organisms in urine identiﬁed in the
microbiology database. Patients who were treated with cefmetazole were compared to those treated
with carbapenems. The clinical and bacteriological cure rates at 4 weeks after completion of therapy
were evaluated.
Results: Two hundred and ﬁfty-six urine cultures growing ESBL-producing organisms were identiﬁed
during the study period. Ten patients treated with cefmetazole and 12 patients treated with
carbapenems were evaluated. There was no difference in clinical (9/10 vs. 12/12, p = 0.46) or
bacteriological cure rate (5/7 vs. 6/7, p = 1.00) at 4 weeks after the completion of therapy. There was no
difference in the incidence of adverse effects (2/10 vs. 2/12, p = 1.00).
Conclusions: Cefmetazole may be a useful option for the treatment of UTIs caused by ESBL-producing
organisms. Prospective and larger sized studies are needed to conﬁrm our ﬁndings.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The frequency of urinary tract infections (UTIs) caused by
Enterobacteriaceae producing extended-spectrum beta-lactamases
(ESBLs) is increasing worldwide, even in community settings.1
Although there are few nationwide reports on ESBL-producing
organisms in Japan,2 data have shown that CTX-M (particularly
CTX-M-9) in Escherichia coli is prevalent in Japan;3,4 the prevalence
of ESBL-producing organisms in our hospital has also been
increasing (unpublished data). In 2010, the Clinical and Laboratory
Standards Institute (CLSI) changed the susceptibility breakpoint of
Enterobacteriaceae against cephalosporins and aztreonam, and the
routine detection of ESBLs in regular bacterial culture was not
recommended for therapeutic purposes;5 however their detection
in routine culture has continued in many microbiology laborato-
ries in Japan.* Corresponding author. Tel.: +81 75 593 4111; fax: +81 75 581 6935.
E-mail address: asakodoi@gmail.com (A. Doi).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.09.010It is recommended that infections caused by ESBL-producing
organisms, especially serious ones such as bacteremia, should be
treated with carbapenems.1,6 Carbapenems are the drug of choice
for the treatment of infections caused by highly-resistant Gram-
negative bacteria, however the increase in their use could lead to
the selection of carbapenem-resistant organisms and have
undesirable effects on hospitals and in the community with
regard to microbial resistance.
Although there are few published reports on clinical efﬁcacy,
cephamycins are known to be stable against the hydrolytic activity
of ESBLs.6–8 However, a decrease in the expression of outer
membrane protein can occur and the production of inducible or
constitutive AmpC beta-lactamase during treatment may result in
treatment failure.9,10 Because of this, cephamycins are not
recommended as ﬁrst-line therapy for serious infections caused
by ESBL-producing organisms, despite their good in vitro activity. If
acquired AmpC beta-lactamases co-exist with ESBLs, the efﬁcacy of
cephamycins is disrupted; however, a report has shown that
plasmid-mediated AmpC beta-lactamases are rare in Kinki region
where our hospital is located.11 To date, ﬂomoxef is the onlyses. Published by Elsevier Ltd. All rights reserved.
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clinical study has ever evaluated the role of cefmetazole – the only
cephamycin available in Japan with a CLSI breakpoint for
Enterobacteriaceae – for infections caused by ESBL-producing
bacteria.
The purpose of the current study was to evaluate the efﬁcacy of
cefmetazole against pyelonephritis caused by ESBL-producing
Enterobacteriaceae in comparison to carbapenems, which are
considered the standard therapeutic agents for infections caused
by these organisms.
2. Materials and methods
2.1. Hospital setting and study design
This retrospective study was conducted at a 588-bed tertiary
care teaching hospital from August 2008 to July 2010. In our
hospital, the proportion of ESBL-producing Enterobacteriaceae
during the study period was 15.6% in E. coli, 3.4% in Klebsiella
pneumoniae, 1.9% in Klebsiella oxytoca, and 37.2% in Proteus
mirabilis.
This study compared the efﬁcacy of cefmetazole and carbape-
nems given empirically or as deﬁnitive therapy, which was deﬁned
as antimicrobials given after the susceptibility results were
obtained. A chart review was done for patients with ESBL-
producing organisms such as E. coli, Klebsiella spp, and P. mirabilis in
urine as identiﬁed from the microbiology database for the period
August 2008–July 2010.
Inclusion criteria were: (1) patient age 15 years and a
diagnosis of pyelonephritis by clinicians based on bacteriuria
with >104 CFU/ml and pyuria; (2) no foci other than the urinary
tract were found; and (3) patient empirically treated with
cefmetazole or carbapenem from the beginning to the end of
treatment, or treated ﬁrst with other antimicrobials then
changed to cefmetazole or carbapenem based on culture results
(deﬁnitive therapy). Patients with complicated UTIs such as
infections with a neurogenic bladder, urinary stones, and
anatomical abnormalities (i.e., bladder cancer or prostatic
problems) were also included. Cases with positive blood cultures
in addition to urine cultures at the onset of fever were not
excluded. Exclusion criteria included: (1) the occurrence of a
case of new different illness during the treatment of pyelone-
phritis; (2) treatment with both cefmetazole and carbapenem;
(3) an entire duration of treatment of less than 5 days with a drug
to which there was in vitro susceptibility; (4) empirical
treatment for more than 7 days with other antimicrobials to
which there was in vitro susceptibility; and (5) empirical
treatment with carbapenem or cefmetazole changed to another
antimicrobial to which there was in vitro susceptibility. Diabetes
mellitus was deﬁned when patients were treated with oral or
injection anti-diabetic medications. Renal failure was deﬁned in
the case of a serum creatinine >1.5 mg/dl at entry; immunosup-
pression was deﬁned in the case of HIV infection, neutropenia,
cancer, or the consumption of steroids or other immunosup-
pressive agents. The activities of daily living (ADL) score was
estimated based on whether patients were able to move from the
wheelchair by themselves or not. The Pitt bacteremia score is a
scoring system for the prediction of mortality originally used in
intensive care unit (ICU) patients with sepsis, using four factors:
mental status, vital signs, need for mechanical ventilation, and
recent cardiac arrest; this was used for our analysis.13
The primary outcome was the rate of clinical cure at 4 weeks
after the completion of therapy. The secondary outcome was the
rate of bacterial cure at the same point or thereafter if culture
results were not available. Because of the retrospective nature ofthe current study, the approval of the ethics committee at
Rakuwakai Otowa Hospital was not required.
2.2. Bacterial isolates
Identiﬁcation of the isolates and susceptibility testing were
performed using the MicroScan Walkaway 96 SI system (Siemens
Healthcare Diagnostics, Tokyo, Japan), and the minimum inhibito-
ry concentrations (MICs) were interpreted using the CLSI criteria.14
The presence of ESBLs was evaluated by the procedure described in
the CLSI guidelines.14 Isolates positive by initial screen test
according to the MIC criteria were tested with a phenotypic
conﬁrmatory test by disk diffusion method in the hospital
laboratory.
2.3. Statistical analysis
Variables from each group were compared using R version
2.12.2.15 The t-test was used to assess differences in continuous
variables, while Fisher’s exact test was used to assess differences in
dichotomous variables. A two-tailed p < 0.05 was considered
statistically signiﬁcant.
3. Results
Two hundred and ﬁfty-ﬁve urine cultures with ESBL-producing
organisms were identiﬁed. Susceptibilities to cefmetazole and
meropenem for all Enterobacteriaceae from urine specimens
identiﬁed during the study period were 99.6% and 100%,
respectively. We excluded 131 patients who were considered to
have colonization only, 10 patients with insufﬁcient data, six
patients under 15 years of age, 12 patients who were considered to
have cystitis, 12 patients who developed comorbid conditions
during treatment such as pneumonia, eight patients who were
treated with both cefmetazole and meropenem, ﬁve patients who
were administered other antimicrobials to which there was
susceptibility after cefmetazole and carbapenems, 48 patients
treated with other antimicrobials, and one patient whose
treatment duration was less than 5 days (Figure 1). As a result,
22 eligible patients were included. Ten patients were treated with
cefmetazole and 12 patients were treated with carbapenems, and
all the relevant isolates were susceptible to cefmetazole or
carbapenems. Meropenem or imipenem/cilastatin was used in
the carbapenem group.
Patient characteristics are shown in Table 1. There was no
difference between the groups in patient characteristics except for
the presence of diabetes mellitus (5/10 vs. 0/12, p = 0.010),
concurrent bacteremia (0/7 vs. 8/12, p = 0.013), and the use of
antimicrobials other than cefmetazole or carbapenems initially as
empirical treatment (9/10 vs. 5/12, p = 0.031). Other complications
found in the cefmetazole group were cerebral infarction (two
patients) and fracture without urinary incontinence (one patient),
and in the carbapenem group one patient had a spinal cord injury.
There was no signiﬁcant difference in age, gender, ADL score,
complicated UTI, immunosuppression, other comorbidities, inpa-
tient treatment for UTI, change of antimicrobials, or treatment
duration between the groups.
There was no difference in clinical cure rate at 4 weeks (9/10 vs.
12/12, p = 0.46) or bacteriological cure rate (5/7 vs. 6/7, p = 1.00).
One patient in the cefmetazole group had recurrence of
pyelonephritis concurrent with pneumonia after incomplete
treatment. The urine culture grew ESBL-producing E. coli which
had the same sensitivity results as that recovered from the urine
before treatment. There was no difference in the incidence of
adverse effects (2/10 vs. 2/12, p = 1.00) (Table 2).
Table 1
Comparison of patient characteristics between the cefmetazole group and the carbapenem group
Cefmetazole Carbapenem p-Value
Number of patients 10 12
Sex 3/10 (30) 7/12 (58.3) 0.231
Age, mean years 77.0 78.75 0.603
ADLa 1/10 (10) 5/12 (41.7) 0.162
Bacteremia 0/7 (0) 8/12 (66.7) 0.013
Pitt bacteremia score NA 1.92
Urine culture E. coli 9/10 (90) E. coli 12/12 (100) 0.455
K. pneumoniae 1/10 (10) Klebsiella sp 0/12 (0) 0.455
P. mirabilis 0/10 (0) P. mirabilis 1/12 (8.3) 1.000
Inpatient 9/10 (90) 8/12 (66.7) 0.323
Complicated UTI 5/10 (50) 10/12 (83.3) 0.172
Urinary catheter inserted 5/10 (50) 6/12 (50) 1.000
Diabetes mellitus 5/10 (50) 0/12 (0) 0.010
Renal failure 1/10 (10) 4/12 (33.3) 0.323
Immunosuppression 0/10 (0) 2/12 (16.7) 0.481
Other complications 3/10 (30) 1/12 (8.3) 0.293
Prior antibiotic use within 3 months 7/10 (70) 7/12 (58.3) 0.675
Change of antimicrobials 9/10 (90) 5/12 (41.7) 0.031
Duration, mean days 11.9 12.5 0.771
NA, data not available; UTI, urinary tract infection.
a Activities of daily living, based on whether patients were able to move from a wheelchair by themselves (=1) or not (=0).
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We are now practicing in an aging population, and the majority
of infections in elderly patients from nursing-care facilities are
pneumonia and UTIs. Risk factors for ESBL-producing organisms
are recent antibiotic use, residence in a long-term care facility,
recent hospitalization, age 65 years, and male sex.1,16–19 Elderly255 urine cultures which were positi ve  for 
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Figure 1. Enrollmentpatients who are repeatedly hospitalized often acquire multidrug-
resistant organisms, such as those producing ESBLs. Infections
caused by CTX-M ESBL-producing E. coli in the community setting
are on the increase.1,16,20 While this may warrant the choice of a
carbapenem as empiric therapy for the treatment of serious
community-acquired infections due to the lack of any other
convincing antimicrobials,21,22 we have to spare these as much asded
a
ion less than 5 days
ded
r illness   
cefmetazole and carbapenems








 of the patients.
Table 2
Comparison of the outcome between the two treatment groups
Cefmetazole Carbapenem p-Value
Clinical cure rate at 4 weeks after treatment 9/10 (90) 12/12 (100) 0.46
Microbiological cure rate at 4 weeks after treatment 5/7 (71.4) 6/7 (85.7) 1.00
Adverse effects 2/10 (20) 2/12 (16.7) 1.00
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the market.
Drugs other than carbapenems such as ﬂuoroquinolones and
amoxicillin/clavulanate have been recommended for the treat-
ment of UTIs if the organisms are susceptible in vitro.1,5 The
efﬁcacy of fosfomycin and nitrofurantoin has recently been
evaluated for community-acquired UTIs caused by ESBL-producing
organisms23–27 and they have been added to the current
armamentarium for ﬁrst-line empirical therapy of uncomplicated
lower UTIs.16,28 beta-Lactam/beta-lactamase inhibitors
(BLBLIs)29,30 and ﬂomoxef9,12 have also been evaluated in clinical
studies of infections caused by ESBL-producing organisms and
BLBLIs have been used for the treatment of UTIs due to such
organisms.8 A recent post-hoc analysis comparing BLBLIs with
carbapenems for the treatment of blood stream infections showed
there was no difference in mortality or duration of hospital stay
between the groups.31 However, piperacillin–tazobactam is
affected by the inoculum effect in vitro,32 and inhibitor-resistant
CTX-M beta-lactamases might evolve under exposure to BLBLIs;30
there is a case report of treatment failure in prosthetic valve
endocarditis due to the development of resistance during
therapy.33 Because of these mixed results, the use of BLBLIs in
the treatment of infections caused by ESBL-producing bacteria
remains controversial.
In this study, there was no difference between the efﬁcacy of
cefmetazole and that of meropenem in terms of clinical and
bacteriological cure rates at 4 weeks after the completion of therapy.
There were several limitations to this study. First, more patients
with a low ADL were included in the cefmetazole group, and more
complicated UTIs were seen in the carbapenem group. Also, more
bacteremia was seen in the latter group. This may have resulted
from the use of cefmetazole in aged patients with a low ADL in
order to avoid the injudicious use of broad-spectrum antibiotics. In
addition, the tendency to use a carbapenem in bacteremic cases
might have affected the outcome, because more serious cases
might have been included in the carbapenem group than in the
cefmetazole group. Likewise, there was a signiﬁcant difference in
initial empirical treatment. More patients in the cefmetazole group
received antimicrobials other than either cefmetazole or carba-
penems. This may be because cefmetazole was not as likely to be
chosen as the initial empiric therapeutic agent before susceptibili-
ty test results became available, since its spectrum is not broad
enough. Furthermore, signiﬁcantly more diabetic patients were
included in the cefmetazole group; the reason for this is unclear.
Selection bias might have caused these differences in the two
groups. To overcome these limitations, prospective and larger
sized studies are needed.
In conclusion, cefmetazole was successfully used for the
treatment of UTIs caused by ESBL-producing organisms. Cefme-
tazole may be an option to spare carbapenem use and this may aid
in better antimicrobial stewardship.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enter-
obacteriaceae: an emerging public-health concern. Lancet Infect Dis
2008;8:159–66.2. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, et al. In vitro
susceptibilities to levoﬂoxacin and various antibacterial agents of 12,919
clinical isolates obtained from 72 centers in 2007 (in Japanese). Jpn J Antibiot
2009;62:346–70.
3. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the
prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in
Japan by clonal spread. J Antimicrob Chemother 2009;63:72–9.
4. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical and molecular epidemiology of
extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella
pneumoniae in a long-term study from Japan. Eur J Clin Microbiol Infect Dis
2011;30:83–7.
5. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Twentieth informational supplement. M100-S20.
Wayne, PA: CLSI; 2010.
6. Harada S, Ishii Y, Yamaguchi K. Extended-spectrum beta-lactamases: implica-
tions for the clinical laboratory and therapy. Korean J Lab Med 2008;28:401–12.
7. Paterson DL, Daveson K. Cefoxitin, cefotetan and other cephamycins (cefme-
tazole and ﬂomoxef). In: Grayson ML, editor. Kucers’ The use of antibiotics.
London: Edward Arnold; 2010. p. 301–10.
8. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical up-
date. Clin Microbiol Rev 2005;18:657–86.
9. Lee CH, Chu C, Liu JW, Chen YS, Chiu CJ, Su LH. Collateral damage of ﬂomoxef
therapy: in vivo development of porin deﬁciency and acquisition of blaDHA-1
leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae
producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother
2007;60:410–3.
10. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem
resistance in Klebsiella pneumoniae is associated with the combination of
ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer
membrane protein. Antimicrob Agents Chemother 1997;41:563–9.
11. Yamasaki K, Komatsu M, Abe N, Fukuda S, Miyamoto Y, Higuchi T, et al.
Laboratory surveillance for prospective plasmid-mediated AmpC beta-lacta-
mases in the Kinki region of Japan. J Clin Microbiol 2010;48:3267–73.
12. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Klebsiella pneu-
moniae bacteraemia with carbapenems or ﬂomoxef: a retrospective study and
laboratory analysis of the isolates. J Antimicrob Chemother 2006;58:1074–7.
13. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, et al. Scoring systems for
prediction of mortality in patients with intensive care unit-acquired sepsis: a
comparison of the Pitt bacteremia score and the acute physiology and chronic
health evaluation II scoring systems. Shock 2009;31:146–50.
14. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Twenty-ﬁrst informational supplement. M100-
S21. Wayne, PA: CLSI; 2011.
15. R foundation for Statistical Computing. Available at: http://www.r-project.org
(accessed January 11, 2012).
16. Rodrı´guez-Ban˜o J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al.
Community infections caused by extended-spectrum beta-lactamase-produc-
ing Escherichia coli. Arch Intern Med 2008;168:1897–902.
17. Ben-Ami R, Rodrı´guez-Ban˜o J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A
multinational survey of risk factors for infection with extended-spectrum beta-
lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect
Dis 2009;49:682–90.
18. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae
producing extended-spectrum beta-lactamases (ESBLs) in the community. J
Antimicrob Chemother 2005;56:52–9.
19. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, et al.
National multicenter study of predictors and outcomes of bacteremia upon
hospital admission caused by Enterobacteriaceae producing extended-spectrum
beta-lactamases. Antimicrob Agents Chemother 2010;54:5099–104.
20. Canto´n R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol
2006;9:466–75.
21. Endimiani A, Luzzaro F, Perilli M, Lombardi G, Coll A, Tamborini A, et al.
Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 ex-
tended-spectrum beta-lactamase: treatment outcome of patients receiving
imipenem or ciproﬂoxacin. Clin Infect Dis 2004;38:243–51.
22. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al.
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of produc-
tion of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31–7.
23. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for
the treatment of multidrug-resistant, including extended-spectrum beta-lac-
tamase producing, Enterobacteriaceae infections: a systematic review. Lancet
Infect Dis 2010;10:43–50.
24. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al.
Carbapenem versus fosfomycin tromethanol in the treatment of extended-
spectrum beta-lactamase-producing Escherichia coli-related complicated lower
urinary tract infection. J Chemother 2010;22:355–7.
A. Doi et al. / International Journal of Infectious Diseases 17 (2013) e159–e163 e16325. Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobac-
teriaceae:changingepidemiologyanddrugtreatmentchoices.Drugs 2010;70:313–23.
26. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Ferna´ndez S, et al. Parallel
increase in community use of fosfomycin and resistance to fosfomycin in
extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Anti-
microb Chemother 2010;65:2459–63.
27. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae:
changing landscape and implications for therapy. Drugs 2012;72:1–16.
28. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with
urinary tract infections caused by extended-spectrum-beta-lactamase-produc-
ing Escherichia coli. Antimicrob Agents Chemother 2010;54:4006–8.
29. Rodrı´guez-Ban˜o J, Navarro MD, Retamar P, Pico´n E, Pascual A. b-Lactam/b-
lactam inhibitor combinations for the treatment of bacteremia due to extend-
ed-spectrum b-lactamase-producing Escherichia coli: a post hoc analysis of
prospective cohorts. Clin Infect Dis 2012;54:167–74.30. Ripoll A, Baquero F, Novais Aˆ, Rodrı´guez-Domı´nguez MJ, Turrient MC, Canto´n R,
et al. In vitro selection of variants resistant to beta-lactams plus beta-lactamase
inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario? Anti-
microb Agents Chemother 2011;55:4530–6.
31. Owens RC. An overview of harms associated with beta-lactam antimicrobials:
where do the carbapenems ﬁt in? Crit Care 2008;12(Suppl 4):S3.
32. Thomson KS, Moland ES. Cefepime, piperacillin–tazobactam, and the
inoculum effect in tests with extended-spectrum beta-lactamase-produc-
ing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:
3548–54.
33. Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, Navon
Venezia S, et al. Endocarditis caused by extended-spectrum-beta-lactamase-
producing Klebsiella pneumoniae: emergence of resistance to ciproﬂoxacin and
piperacillin–tazobactam during treatment despite initial susceptibility. Anti-
microb Agents Chemother 2006;50:3179–82.
